George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
RUA about to hit the big league
Volume will go up 10x over the next 6 months
10 Reasons I like RUA and have increased my investment recently. Please do your own research.
1. £32m market cap (as I write), small market cap
2. Strong cash position, ~£6.2m when last declared
3. Very large total addressable market (TAM), ~$5bn market for patches & grafts, ~$8bn market for heart valve
4. Steady long term uptrend however well down from highs of ~180p, as said above, the market cap is small
5. Good quality II’s onboard, Amati global investors bought 8.07% of the company at 120p last December
6. Equity Development Research Broker Target is currently 523p, this target has been steadily increasing based on progress made, I expect it to carry on increasing
7. RUA owns Elast-Eon, a bio stable polymer used in medical devices, it has been used in 6.3m long-term cardiovascular implants and has NEVER had a failure
8. RUA are now moving towards making their own products rather than just supplying others their world class material, the product pipeline is impressive
9. Vascular graft FDA 501k submission is imminent, the approval process is ‘months’ not ‘years’ as it’s a medical device not a drug, the company expects product launch this financial year. RUA have a steady pipeline of products coming down the track after the first graft.
“Dr Caroline Stretton, Group MD of RUA, said: "I am delighted that the work by the third-party testing house has confirmed our internal work on resolving the cellulose contamination issue and look forward to the final submission of our 510k and receiving feedback on our products from EACTS. We remain on target to launch the world's first non-biogenically sealed grafts by the end of this financial year."
10. RUA have a heart valve project working towards ‘design freeze’. The heart valve project alone could be sold for 10x the current market cap.
“Potential buyers of new heart valve technology tend to get really interested around the time of the human trial phase, Brown observes.
Take-out values have been US$300-500mln,he points out. What we’ve got is substantially more disruptive.”
In summary: Great IP, large TAM, small market cap, strong cash position & near term catalysts
We’ll see the previous ATH unsurpassed within a few months, this is a great company and management are delivering at pace
10 bagger plus on sale
Bought more today
Can’t see it sub 100p for long, buyers here are on a winner
Post FDA submission I can see a much higher trading range emerge
Lots on offer here & the herd aren’t on to it
Unlike many in the junior sector TGR management are delivering at a very impressive pace
Great long term share, value hunters will arrive very soon at this price
First buy was 90p and added up to 110p so far
Happy to add sub ~130p as funds come available
Serious bagger potential LT
Some great posts guys
Doyle - how quickly could Platypus be brought online please?
I can’t see a better stock on AIM to buy right now
Sp feels low down here, company delivering & production / potential getting very significant
Then there is the Copper replacement ‘moonshot’
130-150p seems ‘fair’
Added some, late move on…
This will breakout higher soon in my view
Very undervalued
This could be a steady climber from here, great entry point for the LT
Imagine factoring in today’s Oil & Gas prices to this article from April when IC thought we were very undervalued
Sp gone up a little bit and the underlying commodity has mooned !!!!
https://www.investorschronicle.co.uk/ideas/2021/04/20/priced-for-a-slick-recovery/
Cheers all, sounds like a waiting game, it’s in the watchlist again
Like I said, great asset for sure
When do people think this will be resolved ? Great asset, once sorted it should move
Great growth story, well funded & lots to come
PMG company PR is poor, shame really
Good RNS, I’m in
Added more, next leg up soon
Added more, cheap now